SAIF Partners IV L.P. Amends Sinovac Biotech Holdings Filing

TL;DR

SAIF Partners IV L.P. updated its Sinovac Biotech stake filing (13D/A).

AI Summary

SAIF Partners IV L.P. filed an amendment (No. 13) to its Schedule 13D on September 12, 2024, regarding its holdings in Sinovac Biotech Ltd. The filing indicates a change in the group members of SAIF IV GP CAPITAL LTD. and SAIF IV GP, L.P. The filing does not disclose specific dollar amounts or new share counts but signifies an update to their beneficial ownership reporting.

Why It Matters

This amendment signals a change in the reporting entity's structure or holdings related to Sinovac Biotech, which could impact investor perception and future trading activity.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings can indicate shifts in significant shareholder positions, potentially affecting stock price and liquidity.

Key Players & Entities

• SAIF Partners IV L.P. (company) — Filing entity
• Sinovac Biotech Ltd. (company) — Subject company
• SAIF IV GP CAPITAL LTD. (company) — Group member
• SAIF IV GP, L.P. (company) — Group member
• Andrew Y. Yan (person) — Person authorized to receive communications

FAQ

Key Financial Figures

• $0.001 — elating to the common shares, par value $0.001 per share (the “Common Shares&rdq

Filing Documents

• tm2423909d1_sc13da.htm (SC 13D/A) — 65KB
• tm2423909d1_ex7-08.htm (EX-7.08) — 16KB
• 0001104659-24-099309.txt ( ) — 83KB

Contracts, Arrangements, Understandings or Relationships

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

is hereby amended and supplemented as follows

Item 6 is hereby amended and supplemented as follows: On September 12, 2024, the Seller and the Buyer entered into an amendment No.6 to the Investment Agreement (the “Amendment No.6”) to extend the period of the Buyer’s right of first refusal period (“ROFR Period”), during which the Buyer has a right to elect to purchase all of the shares of the Issuer that the Seller would sell to any person (other than any of its affiliate or an existing limited partner) at the same price and subject to the same material terms and conditions proposed by such person under the Investment Agreement (as amended), to February 25, 2025. As a result of this extension of the ROFR Period, the period during which the Buyer may exercise the Put Option is also extended in the following manner: (i) if the Buyer and the Seller enter into a share purchase agreement with respect to any shares of the Issuer by February 25, 2025, the Seller may exercise the Put Option prior to the closing of the sales under such share purchase agreement to sell the Put Option Shares to the Buyer; and (ii) if no such share purchase agreement is executed by February 25, 2025, the Seller may exercise the Put Option within 15 business days immediately after February 25, 2025 to sell the Put Option Shares to the Buyer. References to each of the Investment Agreement and the Amendment No.6 in this Statement are qualified in their entirety by reference to the Investment Agreement and the Amendment No.6, which are attached hereto as exhibits or incorporated herein by reference as if set forth in their entirety herein.

Material to Be Filed as Exhibits

Item 7. Material to Be Filed as Exhibits.

of the Original Schedule 13D is hereby amended and restated

Item 7 of the Original Schedule 13D is hereby amended and restated as follows: Exhibit 7.01 Joint Filing Agreement by and among SAIF Partners IV L.P., SAIF IV GP L.P. and SAIF IV GP Capital Ltd., dated as of June 27, 2017. Exhibit 7.02 Investment Agreement dated November 1, 2022 between SAIF Partner IV L.P. and YZ Healthcare L.P. Exhibit 7.03 Amendment No.1 to Investment Agreement dated March 15, 2023 between SAIF Partner IV L.P. and YZ Healthcare L.P. Exhibit 7.04 Amendment No.2 to Investment Agreement dated May 25, 2023 between SAIF Partner IV L.P. and YZ Healthcare L.P. Exhibit 7.05 Amendment No.3 to Investment Agreement dated September 15, 2023 between SAIF Partner IV L.P. and YZ Healthcare L.P. Exhibit 7.06 Amendment No.4 to Investment Agreement dated December 1, 2023 between SAIF Partner IV L.P. and YZ Healthcare L.P. Exhibit 7.07 Amendment No.5 to Investment Agreement dated June 13, 2024 between SAIF Partner IV L.P. and YZ Healthcare L.P. Exhibit 7.08 Amendment No.6 to Investment Agreement dated September 12, 2024 between SAIF Partner IV L.P. and YZ Healthcare L.P. CUSIP No. P8696W104 Page 6 of 6 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: September 12, 2024 SAIF Partners IV L.P. By: /s/ Andrew Y. Yan Name: Andrew Y. Yan Title: Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P., which is the General Partner of SAIF Partners IV L.P. SAIF IV GP L.P. By: /s/ Andrew Y. Yan Name: Andrew Y. Yan Title: Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P. SAIF IV GP Capital Ltd. By: /s/ Andrew Y. Yan Name: Andrew Y. Yan Title: Director of SAIF IV GP Capital Ltd.